Want to join the conversation?
Pharmaceutical company $MRK said that it has made a collaboration & license agreement with Moderna Therapeutics for the development & commercialization of novel messenger RNA (mRNA)-based personalized cancer vaccines. These have the ability to be synergistic with checkpoint inhibitor therapies, like $MRK's anti-PD-1 therapy, KEYTRUDA.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.